MELANOMA VACCINE--TYROSINASE/GP100 W/ MONTANIDE ISA51 OR GM CSF

黑色素瘤疫苗 - 酪氨酸酶/GP100 W/ Montanide ISA51 或 GM CSF

• 批准号: 6303499
• 负责人: VERNON K. SONDAK
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303499
• 关键词: cellular immunity; clinical research; colony stimulating factor; combination cancer therapy; enzyme linked immunosorbent assay; enzyme therapy; glycoproteins; human subject; human therapy evaluation; immunologic skin test; melanoma; monophenol monooxygenase; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; synthetic vaccines

In nonmalignant conditions, vaccines are not used to treat established disease, but rather to prevent disease from occurring in the first place. We believe that the best way to use vaccines to treat cancers like melanoma is to prevent disease from reoccurring after surgical treatment. We are studying the use of a peptide (protein fragment) vaccine that uses fragments of two proteins known to be on most melanoma cells. The fragments are known to be recognized by immune cells of patients who tissue type (similar to a blood type, also called HLA type) is HLA-A2+. In our study, patients with melanoma of the skin that has not spread to the lymph nodes but is thick enough to be concerning for reoccurrence (stage II melanoma) who are HLA-A2+ are given either the basic peptide vaccine or the vaccine plus GM-CSF injections. GM-CSF is a protein that stimulates the immune system and may improve the effectiveness of the vaccine, but the need for self-injections means that we don+t wish to use it unless it clearly improves the immune response to our vaccine. Injections are spread over a total of 6 months. Before and after vaccination, patients will have white blood cells removed by a procedure known as apheresis. The ability of these white cells to recognize and respond to the peptides before and after vaccination will be compared.

在非恶性疾病中，疫苗不是用来治疗已确定的疾病，而是用来预防疾病的发生。我们认为，使用疫苗治疗黑色素瘤等癌症的最佳方法是防止手术治疗后疾病复发。我们正在研究使用肽（蛋白质片段）疫苗，该疫苗使用已知在大多数黑色素瘤细胞上的两种蛋白质的片段。已知这些片段被组织类型（类似于血型，也称为HLA类型）为HLA-A2+的患者的免疫细胞识别。在我们的研究中，患有皮肤黑色素瘤的HLA-A2+患者没有扩散到淋巴结，但厚度足以考虑复发（II期黑色素瘤），给予基础肽疫苗或疫苗加GM-CSF注射。GM-CSF是一种刺激免疫系统的蛋白质，可能会提高疫苗的有效性，但需要自我注射意味着我们不希望使用它，除非它明显提高对我们疫苗的免疫反应。注射时间总共为6个月。在接种疫苗之前和之后，患者将通过称为单采术的程序去除白色血细胞。将比较这些白色细胞在接种前后识别和应答肽的能力。